Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pfizer, Merck, and Others See a Slowdown in Vaccine Sales, but Anticipate an Autumn Rebound


With all the news and chatter about coronavirus vaccine candidates these days, it might be somewhat surprising to learn that sales of established vaccines have been dropping lately.

An article in Biopharma Drive pointed out that the world's top four vaccine makers -- pharmaceutical giants Pfizer, Merck, Sanofi (NASDAQ: SNY) and GlaxoSmithKline (NYSE: GSK) -- have all experienced notable volume declines in the category.

Sanofi's vaccine sales fell 7% on a year-over-year basis in its most recently reported quarter. Its European peer GlaxoSmithKline suffered sales drops in all components of its vaccines unit, with sales of one of its top products (Shingrix, aimed at preventing shingles) sliding by 16% -- its steepest decline ever.

Continue reading


Source Fool.com

Like: 0
SNY
Share

Comments